Big Food rebrands as obesity drugs reshape demand

586

As appetite-suppressing GLP-1 weight-loss drugs become more widespread in the U.S., global food and beverage giants are expecting long-term changes in consumption patterns and adjusting product strategies accordingly. 

General Mills CEO Jeffrey Harmening:

“We expect GLP-1 and other anti-obesity drugs to have a lasting influence in the food and nutrition landscape, nudging some consumers towards smaller portions and more nutrient-dense protein and fiber-forward foods.”

Rethinking traditional product portfolios

Companies including PepsiCo and Coca‑Cola are emphasising cleaner ingredient lists and compact packaging to align with moderated eating habits. Reformulation, smaller pack sizes, and refreshes of core brands are becoming priorities.

PepsiCo CEO Ramon Laguarta: “I think there are more opportunities than threats, but there are both.”  

Scale of change & financial impact

Industry data suggests up to USD 12 billion in snack sales could be disrupted over the next decade due to dietary changes associated with GLP-1 drug use. Nearly three dozen companies have already referenced GLP-1 drugs or weight-loss trends in earnings calls this year — a sharp increase from prior years.  

Innovation and capital investment

Food companies are directing increased capital expenditure and R&D toward health-forward offerings. Examples include PepsiCo’s new “Simply NKD” line, Coca-Cola boosting production of protein-infused products, and General Mills launching higher protein cereals.

Broader market implications

Executives see a lasting influence of anti-obesity drugs on demand, with smaller portion sizes, more nutrient-dense foods, and “better-for-you” positioning reshaping the broader food industry landscape.